Opinion|Videos|October 28, 2023
Considerations and Challenges Surrounding CAR-T Therapy and Bispecifics
Expert oncologists offer considerations for the use of CAR-T therapy and bispecific antibodies in follicular lymphoma and discuss potential challenges that may limit the use of these agents in clinical practice.
Advertisement
Episodes in this series
Advertisement
Related to this article
In a phase 1 trial, CD19/CD20/CD22 CAR T cells produced complete responses in 83% of patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
“Those of us who work with NK cells have no doubt that they are incredibly powerful at killing cancer cells,” said Veronika Bachanova, MD, PhD.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Pembrolizumab in Metastatic TMB-H Solid Tumors
2
Intismeran Plus Pembrolizumab Reduces Recurrence Risk in Resected Melanoma
3
ESMO 2026: The Presentations That May Transform The Lung Cancer Paradigm
4
Sunvozertinib Now Available in US for EGFR Exon 20+ NSCLC
5